Core Insights - Y-mAbs Therapeutics, Inc. is focused on developing and commercializing novel radiopharmaceuticals and antibody-based therapeutic products for cancer treatment, with a virtual R&D update scheduled to highlight progress in its Radiopharmaceutical Business Unit [1][2] Radiopharmaceutical R&D Update Highlights - The GD2-SADA Phase 1 Clinical Trial (Trial 1001) has completed Part A, demonstrating that GD2-SADA is safe, tolerable, and capable of achieving targeted in vivo conjugation of Lu-DOTA [3][4] - The company plans to initiate a Trial 1001 Bridge study (Part 2A) with an optimized Radiohapten, "Proteus," in the first half of 2026, with data readout expected in the second half of 2026 [3][12] - Part B of Trial 1001 is anticipated to start in the first half of 2027, with data readout expected in the second half of 2027 [3][12] Clinical Trial Details - The primary objective of Trial 1001 is to evaluate the safety and tolerability of GD2-SADA in patients with recurrent or refractory metastatic solid tumors, including small cell lung cancer and high-risk neuroblastoma [4] - In Part A, 22 patients were dosed, with nine patients showing positive GD2 expression and eligible for the therapeutic stage of the study [4] - Results indicated that the GD2-SADA Protein clearance rate is reliably correlated to dose concentrations, providing a roadmap for tailoring the clearance interval prior to isotope administration [4][5] Safety and Tolerability - Both GD2-SADA and Lu-DOTA administrations were generally safe and well-tolerated, with no treatment-related serious adverse events reported [5] Expanded Development Pipeline - Y-mAbs has selected lung cancer, women's cancers, and gastrointestinal cancers as target areas for its expanded oncology franchise [7] - The company plans to file an IND for its first molecular imaging asset by the end of 2025 [7] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company with a focus on novel radioimmunotherapy and antibody-based therapeutic cancer products, including the FDA-approved anti-GD2 therapy DANYELZA [9]

Company announcement No. 14/2025 28 May 2025 Netcompany Group A/S ("Netcompany") hereby announces the following notification received pursuant to section 38 of the Danish Capital Markets Act from Danske Bank A/S, regarding their direct and indirect holdings and voting rights in Netcompany. On 27 May 2025 Danske Bank A/S informed Netcompany, that Danske Bank A/S on 14 March 2023 directly and indirectly via Danica Pension Livsforsikringsaktieselskab, Investeringsforeningen DI, Investeringsforeningen DI Sele ...

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program----Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone-- --Enobosarm 3mg added to semaglut ...

Core Viewpoint - Hyperscale Data, Inc. plans to purchase up to $10 million in XRP to enhance its financial services division through its subsidiary Ault Capital Group, Inc. [1][2] Group 1: Acquisition of XRP - ACG intends to acquire XRP, which will be classified as a crypto asset on the Company's balance sheet at fair value [1] - The acquisition is part of a broader strategy to expand into financial services, including cryptocurrency-based products and tokenization of real-world assets [2][3] - The Company believes that acquiring XRP will enhance liquidity and provide infrastructure support for blockchain-enabled financial products [3] Group 2: Financial Services Expansion - ACG has been successful in the lending business for the past four years and is now looking to broaden its services [2] - The Company aims to leverage XRP for cross-border settlements, real-time payment systems, and decentralized financial applications [3] - This strategic move is seen as a significant step towards integrating modern digital asset solutions into ACG's financial services model [3] Group 3: Future Plans and Divestiture - Hyperscale Data plans to divest ACG by December 31, 2025, focusing solely on data center operations and high-performance computing services thereafter [7] - Until the divestiture, the Company will continue to provide various mission-critical products across multiple industries through ACG [7] - The divestiture will involve an exchange of Series F Preferred Stock for shares of ACG, allowing stockholders to become ACG shareholders [8]

Core Insights - Goliath Resources Limited is initiating its largest drill campaign to date, focusing entirely on the Surebet high-grade gold discovery, with a total of 40,000 meters planned for 2025 [6][7] - The 2025 drill program aims to systematically outline the geometry and extent of the Surebet discovery, which remains open for expansion in all directions [5][6] - The company has significantly increased its land package from 66,608 hectares to 91,518 hectares, controlling 56 kilometers of the Red Line geological trend, enhancing its exploration potential [15] Drilling Program Details - The 2025 drill campaign will utilize 9 rigs and will include testing for the Motherlode causative intrusive gold source and 13 potential Eocene intrusive granitoid dykes that have not been previously tested [5][6] - Infill drilling will focus on increasing the density of pierce points in known veins, particularly in high-grade areas from the Bonanza Zone and Surebet Zone intersection [6][7] - The company has drilled a total of 92,000 meters from 2021 to 2024, resulting in over 400 pierce points that have improved the understanding of the Surebet mineralized system [6][15] Geological Insights - Recent studies indicate that there are two temperature regimes responsible for gold mineralization, suggesting a primary and secondary gold enrichment where veins and dykes intersect [7] - The Surebet discovery has predictable continuity and excellent metallurgy, with gold recoveries from gravity and flotation at 92.2%, including 48.8% free gold from gravity alone [9][15] - Four new mineralized shear zones were identified in 2024, significantly increasing the potential tonnage of the system, which remains open [15] Infrastructure and Location - The Golddigger Property is strategically located within 3 kilometers of the Red Line in the Golden Triangle of British Columbia, an area known for hosting significant mines [8] - The property is accessible by tidewater with direct barge access to Prince Rupert, and is close to communities with necessary infrastructure [10][11] Collaborative Research - Goliath Resources is a member of the Center to Advance the Science of Exploration to Reclamation in Mining (CASERM), which supports research aimed at improving geoscience data acquisition and decision-making in mining [12][16]

Company Overview - Tarkett is a global leader in innovative and sustainable flooring and sports surface solutions, with a history of over 140 years [4] - The company generated a turnover of €3.3 billion in 2024 and employs nearly 12,000 people [4] - Tarkett operates 24 R&D centers, 8 recycling centers, and 35 production sites, serving customers in over 100 countries [4] - The company is committed to circular economy and sustainability through its Tarkett Human-Conscious Design® approach [4] Shareholders' Meeting Information - The Combined Shareholders' Meeting is scheduled for 19 June 2025 at 9:30 a.m. at the Company's head office in Paris La Défense [1] - A preliminary notice of the meeting, including the agenda and draft resolutions, was published in the French Bulletin des Annonces Légales Obligatoires (BALO) on 14 May 2025 [2] - Additional information on attending and voting at the Shareholders' Meeting will be available in the notices and on the Company's website [2][3] Regulatory Compliance - Information related to the Shareholders' Meeting can be consulted on the Company's website under the Investors/Shareholders/Shareholders' Meeting 2025 section [3] - The company ensures that documents and information regarding the Shareholders' Meeting are made available to shareholders in accordance with applicable regulations [3]

Core Insights - Alvotech and Advanz Pharma have expanded their commercial partnership to include three additional biosimilar candidates, enhancing their collaboration in the European market [1][2][8] Group 1: Partnership Details - The new agreement includes biosimilar candidates to Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed candidate, with Alvotech responsible for development and supply, while Advanz Pharma handles registration and commercialization in Europe [2][4] - The agreement encompasses development and commercial milestones totaling up to US$180 million (EUR 160 million) and includes a revenue-sharing model between the partners [2][4] Group 2: Market Potential - The partnership now covers proposed biosimilars referencing over ten originator biologics, with the current addressable market for these products in the relevant countries estimated at least US$13.8 billion [5][3] - Advanz Pharma aims to broaden access to rare disease and specialty medicines through this expanded collaboration, reinforcing its growth strategy in the biosimilars sector [4][3] Group 3: Company Background - Alvotech is focused on developing and manufacturing biosimilar medicines, with a pipeline that includes eight disclosed candidates targeting various diseases, including autoimmune disorders and cancer [7] - Advanz Pharma operates globally, with a focus on specialty, hospital, and rare disease medicines, and has a commercial presence in over 90 countries [10]

Operations and sales continue as usual, honoring all tickets, loyalty points, and Customer benefits, safely connecting Brazil with Azul's industry-leading Customer service. SÃO PAULO, May 28, 2025 /PRNewswire/ -- AZUL S.A. (B3: AZUL4; NYSE: AZUL) ("Azul" or "Company"), the largest airline in Brazil by number of flight departures and destinations, today announced it has entered into Restructuring Support Agreements (the "Agreements") with its key financial stakeholders, including its existing bondholders; la ...

Management Changes - Spar Nord Bank A/S is becoming part of the Nykredit Group, leading to expected changes in the boards of directors and executive managements of the companies within the group [1] - Lasse Nyby, the current CEO of Spar Nord Bank A/S, is proposed to join the Board of Directors of Nykredit Realkredit A/S and will be appointed Deputy Chairman of both Nykredit A/S and Nykredit Realkredit A/S [2][3] - Martin Kudsk Rasmussen will join the Group Executive Board of Nykredit Realkredit A/S, responsible for the entire Banking area in the Nykredit Group [5] Corporate Structure - Nykredit A/S and Nykredit Realkredit A/S are the ultimate parent companies in the Nykredit Group's corporate structure, with business activities primarily conducted through Nykredit Realkredit A/S [4] Executive Board Composition - The Group Executive Board of Nykredit Realkredit A/S will consist of Group Chief Executive Michael Rasmussen and Executive Directors including Martin Kudsk Rasmussen, who will play a significant role in the banking area [6] - The new Board of Directors of Spar Nord is expected to include members from Nykredit Bank A/S, ensuring a unified executive management structure post-merger [10][11] Future Integration - The merger of Nykredit Bank A/S and Spar Nord Bank A/S is expected to take effect in spring 2026, with significant changes to the executive management teams of both banks [13] - Current members of Spar Nord's Executive Management will transition to roles within Nykredit's Group Executive Board, ensuring continuity and expertise during the integration process [14]

Management Changes - Spar Nord Bank A/S is becoming part of the Nykredit Group, leading to changes in the boards of directors and executive managements of the companies within the group [1] - Lasse Nyby, the current CEO of Spar Nord Bank A/S, is proposed to join the Board of Directors of Nykredit Realkredit A/S and will be appointed Deputy Chairman of both Nykredit A/S and Nykredit Realkredit A/S [2][3] - Martin Kudsk Rasmussen will join the Group Executive Board of Nykredit Realkredit A/S, responsible for the entire Banking area within the Nykredit Group [5][6] Corporate Structure - Nykredit A/S and Nykredit Realkredit A/S serve as the ultimate parent companies in the Nykredit Group's corporate structure, with business activities primarily conducted through Nykredit Realkredit A/S [4] Strategic Direction - The integration of Spar Nord into the Nykredit Group aims to enhance customer ownership and market positioning, with a focus on continuing investments in partnerships [7] - The Group Chief Executive, Michael Rasmussen, emphasizes the importance of combining strengths from both banks to compete effectively with larger listed banks [8] Executive Management Changes - The new Board of Directors for Spar Nord Bank A/S is expected to include members from Nykredit Bank A/S, ensuring a unified executive management structure post-merger [10][11] - Changes in executive management will align the leadership of Nykredit Bank A/S and Spar Nord Bank A/S, with key members transitioning between the two [12][14] Future Outlook - The merger of Nykredit Bank A/S and Spar Nord Bank A/S is anticipated to take effect in spring 2026, with significant roles for Martin Kudsk Rasmussen and Carsten Levring Jakobsen in the new structure [13]